1-
Zaviačič, M.;
Zajíčková, M ;
Blažeková, J. ;
Donárová, L. ;
Stvrtina, S. ;
Mikulecký, M. ;
Zaviačič, T. ;
Holomáň, K. and
Breza, J. (2000). Weight, Size, Macroanatomy, and Histology of the Normal Prostate in the Adult Human Female: A Minireview. Journal
Journal of Histotechnology. 23:61-69.
2- Ansari, M.; Begum, D. and Islam, F. (2008). Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia . Ann. Saudi Med., 28 (3): 174–8.
3- Matthew, K.H. H. ; Henry, H.I. Y. ; Kathryn, R. ; Benjamin, N. ; John, P. ; Justin, S. P. ; Christopher, M. H. and Niall, M. C.. (2012 ). Prostate weight is the preferred measure of prostate size in radical rostatectomy cohorts.BJU interrnational , 109(3): 57-63.
4- Lundwall A & Lilja H 1987 Molecular cloning of human prostate specific antigen cDNA. FEBS Letters 214 317.
5- Hara, M. ; Koyanagi, Y. ; Inoue, T. and Fukuyama, T. (1971). Some physico-chemical characteristics of gamma seminoprotein, an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi, 25 322–324.
6- Wang, M.C. ; Valenzuela, L.A. ; Murphy , G.P. and Chu, T.M. (1979) . Purification of a human prostate specific antigen. Investigative Urology 17: 159–163.
7- Sensabaugh, G.H. (1978). Isolation and characterisation of a semenspecific protein from human seminal plasma: a potential new marker for serum identification. Journal of Forensic Science 23 :106–115.
8- Frazier, H. A. ; Humphrey, P. A. ; Burchette, J. L. and Paulson, D. F. (1992). Immunoreactive prostatic specific antigen in male periurethral glands. Journal of Urology. 147 : 246–248.
9- Takayama, T.K. ; Vessela, R.L. ; Brawer, M. K. ; True, L.D. ; Noteboom, J. and Lange, P. H. (1994). Urinary PSA levels after radical prostatectomy. Journal of Urology 151 : 82–87.
10- Schellhammer, P. and Wright, G. J. (1993). Biomolecular and clinical characteristics of PSA and other candidate prostate tumour markers. Urology Clinics of North America 20 :597–606.
11- Edström, A.M. ; Malm, J. ; Frohm, B. ; Martellini, J.A. ; Giwercman, A. ; M. Mörgelin, ; Cole, A.M. and Sørensen, O.E. (2008). The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins J. Immunol., 181 : 3413–3421.
12- Stenman, U. H. ; Leinonen, J. ; Alfthan, H. ; Rannikko, S. ; Tuhkanen, K. and Alfthan, O. (1991). A complex between prostate specific antigen and alpha-1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer. Assay of the complex improves clinical sensitivity for cancer. CancerResearch 51: 222–226.
13- Hunter, C. and Zamiara, P. (2013). The role of prostate-specific antigen (PSA) testing in screening for prostate cancer. UWOMJ 82:1: 17-18.
14- Maduka1, I. C. ; Neboh2, E. E. and Ufelle, S. A. (2015). The relationship between serum cortisol, adrenaline, blood glucose and lipid profile of undergraduate students under examination stress. African Health Sciences 15:131-136.
15- Hammarsten, J.; Hogstedt, B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 39, 151–158.
16- Xiaobing, Q. ; Zhichao, H. ; Xianqin, M. ; Xiangyu, Z. ; Lini, D. and Xiaokun, Z. (2014). Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients. International Urology and Nephrology 46: 499–504.
17- Peter, Sidaway (2015) . Cholesterol level correlates with PSA level in white but not black men. Nature. Reviews Urology. 12:594.
18- Yat-Ching, T. (2011). The role of cholesterol in prostatic diseases. Urological Science 22 :97-102.
19- Sridevi, N. M.D. (2013). Comparative Study of Prostatic Diseases BPH and prostatic cancer by estimating serum PAP and total PSA levels. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-ISSN: 2278-3008, p-ISSN:2319-7676. Volume 8, Issue 6, : 44-47 .
20- Anusha, A.M. ; Ranjith, S. and Annamala, P.T. (2015). Correlation between prostate specific antigen and acid phosphatase with histopathological findings in various prostatic pathologies. SSRG International Journal of Medical Science (SSRG-IJMS) – volume 2 Issue 6:1-6 .
21- Mathur, R.P. ; Nayak, S. ; Sivaramakrishnan, R. ; Jain, V. (2014). Role of alpha blockers in hypertension with benign prostatic hyperplasia. Journal of the Association of Physicians of India. 62 : 40-44.
22- Sanchez, P. ; Torres, J.M. ; Castro , B. ; Olmo , A. ; del Moral, R.G. and Ortega, E. (2013). Expression of steroid 5a-reductase isozymes in prostate of adult rats after environmental stress. FEBS Journal 280 : 93–101.
23- Jin, B. ; Turner, L. ; walters, w. A. and Handelsman, D. J. (1996). The effects of chronic high dose androgen or estrogen treatment on the human prostate. J. Clin. Endocrinol. Metab. 81, 4290–4295 .
24- Ho, C. K. M. and Habib, F. K.(2011). Estrogen and androgen signaling in the pathogenesis of BPH. Nat. Rev. Urol. 8, 29–41:10.1038.
25- Harman, SM. ; Metter, EJ. ; Tobin, JD. ; Pearson, J. ; Blackman. MR, et al. (2001). Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 86: 724–731.
26- Carson, C. and Rittmaster, R. (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. UROLOGY 61 (Supplement 4A): 2-7.
27- Kaplan, SA. ; Roehrborn, CG. ; McConnell, JD. ; Meehan, AG. ; Surynawanshi, S. ; et al. (2008). Long‑term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J. Urol. 180: 1030–2.
28- Long, XJ. ; Lin, S. ; Sun, Y. N. and Zheng, Z. F.(2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac. J. Cancer Prev. 13(8):4097-4100.
29- Sharma, N. ; Sood, S. ; Kaushik, G. G. ; Ali, Z. (2013). Risk of prostate cancer and its correlation with different biochemical parameters in non diabetic men. Int J Res Med Sci. 1(4):476-481.
30- Lekili, M. ; Muezzinoglu, T. ; Uyanik, B. S. and Buyuksu, C. (2006). Serum lipid levels in benign prostatic hyperplasia. World J. Urol. 24: 210-3.
31- Nandeesha, H. ; Koner, B. C. ; Dorairajan, L. N. and Sen, S. K. (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 370: 89-93.
32- Gökce, A. ; Yalcinkaya, F. R. ; Davarci, M. and Baibay, M. D. (2010). The relationship between serum lipid levels and benign prostatic hyperplasia. The New Journal of Medicine 27: 148-150.
33- Anusha, A.M. 1. ; Ranjith, S. and Annamala, P.T. (2015). Correlation between Prostate Specific antigen and acid phosphatase with histopathological findings in various prostatic pathologies. International Journal of Medical Science 2 (6) :1-6.
34- Igwe, C.U. 1. ; Ikaraoha, C.I. ; Ogunlewe, J.O. ; Nwobu, G.O. ; Duru, L.A.D. and Mokogwu, A.T.H. (2004). The Study Of Serum Prostate Specific Antigen And Phosphatase Isoenzymes Activity As Diagnostic Parameters In Patients With Prostate Cancer In Nigeria. OJHAS: Vol. 3, Issue 3: 1-6.
35- Locke, JA. ; et al. (2009). A novel communication role for CYP17A1 in the progression of castrationresistantm prostate cancer. Prostate. 2009; 69:928–937. [PubMed: 19267349].
36- Nacusi, L. P. and Tindall, D. J. (2011). Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol. ; 8(7): 378–384.
37- Sigurdardottir, L. G. (2015). The role of circadian disruption in prostate cancer development. Doctoral committee:Unnur A. Valdimarsdóttir, Lorelei A. Mucci,Katja Fall, Eirikur Jonsson and Vilmundur Gudnason . University of Iceland.
38- Zeng, Q. ; Xu, C. ; Liu, Z. ; Wang, H. ; Yang, B. ; Xu , W. ; Jin, T. ; Wu, C. ; Huang, G. ; Li, Z. ; Wang, B. and Sun, Y.(2012). Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging Men. Asian Journal of Andrology. 14: 773–777.
39- Budak, Y. ; Huysal, K. ; Karadağ, E. ; Demirci, H. ; Güzelsoy, M. and Coban, S. (2016). Associations between sex hormones and lower urinary tract symptoms in middle-aged men. Turk J. Endocrinol. Metab. 20:123-126.
40- Nakhla, A. M. ; Romas, N. A. and Rosner, W. (1997). Estradiol activates the prostate androgen receptor and prostate specific antigen secretion through the intermediacy of sex hormone-binding globulin. The Journal of biological chemistry. 272 (11) : 6838–6841.
41- Collins, A.T. ; Zhiming, B. ; Gilmore, K. and Neal, D.E.(1996). Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor. J. Endocrinol. 143:269-77.
42- Mustafa, M. ; Çelik2, M. ; Horsanli, O. ; Horuz1, R. and Küçükcan, A.(2011). Relationship between serum PSA and testosterone levels in two different geographic regions of Turkey. Turkish Journal of Urology 37(1):9-13.
43- Reis, L. O. ; Denardi,F. ; Faria, E. F. and Silva, E. D.(2014). Correlation Between Testosterone and PSA kinetics in metastatic prostate cancer patients treated with diverse chemical castrations. American Journal of Men’s Health. Vol. 9(5): 430–434.
44- Gray, A. ; Feldman, H.A. ; McKinlay, J.B. and Longcope, C. (1991). Age, disease, and changing sex hormone levels in middle-aging men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73: 1016–25.